LarryQC_SD said:Relative and absolute effects need reading together.
This is where I part company with the consensus forming above. Two drugs, two side-effect profiles, one price. The efficiency argument only works if the tolerability really is better than dose-escalating a single agent, and I have not seen that demonstrated head to head.
Adding the numbers, since they settle part of this. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
kate.chem said:Two drugs, two side-effect profiles, one price.
There is a second half to this that has not been said yet. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from JessicaH_TX — and this may be the naive question:
How to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases?
Closing the loop on my own question.
Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.